Cover Image
市場調查報告書

醫藥品分析:Masitinib

Drug Overview: Masitinib

出版商 Datamonitor Healthcare 商品編碼 603994
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品分析:Masitinib Drug Overview: Masitinib
出版日期: 2018年01月18日 內容資訊: 英文 45 Pages
簡介

本報告提供口服蛋白酪氨酸激梅抑制劑,Masitinib 調查分析,產品簡介相關的系統性資訊。

產品簡介

  • Masitinib:前列腺癌症
  • Masitinib:大腸癌症 (CRC)
  • Masitinib:氣喘
  • Masitinib:胰臟癌症

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0144695

Drug Overview

Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase. This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.

TABLE OF CONTENTS

5 Product Profiles

5 masitinib : Prostate cancer

17 masitinib : Colorectal cancer (CRC)

31 masitinib : Asthma

38 masitinib : Pancreatic cancer

LIST OF FIGURES

  • 10 Figure 1: Masitinib for prostate cancer - SWOT analysis
  • 11 Figure 2: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • 12 Figure 3: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • 14 Figure 4: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
  • 22 Figure 5: Masitinib for colorectal cancer - SWOT analysis
  • 23 Figure 6: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • 24 Figure 7: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • 26 Figure 8: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 34 Figure 9: Masitinib for asthma - SWOT analysis
  • 35 Figure 10: Datamonitor Healthcare's drug assessment summary of masitinib in asthma
  • 36 Figure 11: Datamonitor Healthcare's drug assessment summary of masitinib in asthma
  • 41 Figure 12: Masitinib for pancreatic cancer - SWOT analysis
  • 42 Figure 13: Datamonitor Healthcare's drug assessment summary of masitinib in pancreatic cancer
  • 43 Figure 14: Datamonitor Healthcare's drug assessment summary of masitinib in pancreatic cancer

LIST OF TABLES

  • 6 Table 1: Masitinib drug profile
  • 7 Table 2: Masitinib Phase III trial in prostate cancer
  • 9 Table 3: Masitinib Phase II data in prostate cancer
  • 15 Table 4: Masitinib sales for prostate cancer across the five major EU markets, by country ($m), 2017-26
  • 17 Table 5: Masitinib drug profile
  • 19 Table 6: Masitinib Phase III trial in colorectal cancer
  • 21 Table 7: Masitinib early-phase data in colorectal cancer
  • 27 Table 8: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 29 Table 9: Patients treated with masitinib across the US and five major EU markets, by country, 2016-25
  • 32 Table 10: Masitinib drug profile
  • 33 Table 11: Masitinib Phase III trials in asthma
  • 39 Table 12: Masitinib drug profile
  • 40 Table 13: Masitinib Phase III data in pancreatic cancer

 

Back to Top